The p53 tumour suppressor induces cell cycle arrest and apoptosis in response to cellular stresses. p53 is inactivated by various cellular and viral factors. We set out to generate regulatable p53 derivatives that are highly inducible by synthetic ligands, escape inactivation and eciently induce apoptosis. We have generated Ligand Inducible Chimeric Tumour Suppressors (LI-CTS), that are inactive unless provided with arti®cial ligands. They are resistant to inactivation, due to the replacement of domains that mediate p53 inhibition by heterologous sequences. LI-CTS are activated by micromolar concentrations of ligand in a variety of cell lines. Following ligand addition, they translocate to the nucleus, activate p53 inducible genes and induce apoptosis. We have established human head and neck squamous cell carcinoma lines that stably express LI-CTS, which are inducible. These lines form tumours in nude mice in the absence of ligand. Addition of ligand inhibits tumour formation, and moreover, regresses established tumours by apoptosis. Although regulatable p53 expression has been achieved previously, our study provides the ®rst demonstration of regulatable in vivo regression of tumours in a p53 based approach. Regulated inhibition and regression of tumours with a ligand inducible chimeric tumour suppressor could provide a novel approach to p53 based gene therapy.
Introduction
The tumour suppressor, p53, is mutated in about half of human cancers (Hollstein et al., 1991) . Lack of functional p53 is linked to tumour development in mice (Donehower et al., 1992) and humans aicted with the Li-Fraumeni syndrome (Malkin et al., 1990) . p53 is normally expressed at low levels and is activated by diverse signals (Giaccia and Kastan, 1998) . p53 has roles in cellular senescence (Bond et al., 1996) , dierentiation (Choi and Donehower, 1999) , cell cycle arrest (Deng et al., 1995; Waldman et al., 1996) and apoptosis (Attardi et al., 1996; Yonish-Rouach et al., 1995) , depending on cell type and inducer (review Bates and Vousden, 1996) . p53 activates transcription of genes such as p21 WAF1/CIP1 , which is involved in cell cycle arrest (Brugarolas et al., 1995; Waldman et al., 1996) , and Bax, which promotes apoptosis (Miyashita et al., 1994; Miyashita and Reed, 1995) . p53 mutants with selective defects in the activation of the Bax promoter do not induce apoptosis (Friedlander et al., 1996) . p53 may also induce apoptosis through its eects on IGF-BP3 (Buckbinder et al., 1995) , the mammalian homologue of Drosophila seven in absentia gene (Nemani et al., 1996) , PAG 608 (Israeli et al., 1997) and other genes identi®ed by dierential screening (Polyak et al., 1997) . However, p53 also induces apoptosis by transcription independent mechanisms (Caelles et al., 1994; Haupt et al., 1995) .
Various cellular and viral proteins negatively regulate p53. It is inactivated by some p53 mutants by a trans-dominant mechanism (Milner and Medcalf, 1991) , and by HDM2 through proteasome mediated degradation Kubbutat et al., 1997) . p14
Arf (Stott et al., 1998) , p19 Arf (Pomerantz et al., 1998) and Rb (Hsieh et al., 1999) aect the p53-HDM2 feedback loop. HPV16 and 18 E6 proteins bind to p53 and stimulate its degradation (Schener et al., 1990) . Adenovirus E1B 55K forms a complex with p53 (Sarnow et al., 1982) and inhibits its transcriptional activity (Yew et al., 1994) , whereas E1B 19K blocks p53 mediated transcriptional repression (Sabbatini et al., 1995) . SV40 large T antigen also inhibits the transactivation function of p53 (Jiang et al., 1993) . Hence, developing a strongly inducible p53 should take into account the negative regulatory factors, without compromising its basic tumour suppressor functions.
p53 is usually inactivated in human tumours. Various approaches have been adopted to restore p53 functions. p53 mutants have been rescued with peptides (Hupp et al., 1995; Selivanova et al., 1997) , intragenic suppressor mutations (Brachmann et al., 1998) or by changing the structure of the mutant protein (Wieczorek et al., 1996) . Peptides can release p53 from the complex with HDM2 and promote apoptosis (Bottger et al., 1997; Wasylyk et al., 1999) . p53 delivery with retroviral or adenoviral vectors is promising, since it inhibits growth of both tumour cells (GomezManzano et al., 1996; Mukhopadhyay and Roth, 1998; Slack et al., 1996) and xenografts in nude mice and has been successful in Phase I human trials Schuler et al., 1998) . p53 delivery increases the sensitivity of tumours to radiotherapy (Gallardo et al., 1996; Pirollo et al., 1997) and chemotherapy . There is a derivative of p53, the Chimeric Tumour Suppressor 1 (CTS1), that has enhanced properties (Conseiller et al., 1998) , since it has the VP16 activation domain and an arti®cial leucine zipper in the place of the N-and Cterminal domains that mediate p53 down-regulation ( Figure 1A) , and it is active in tumour cells and not in normal cells. However, CTS1 is not ideal since it is constitutively active, and it could be improved and made safer if it was regulated. Ligand inducible systems have been used to regulate p53 (Bennett et al., 1998; Vater et al., 1996) . We have generated Ligand Inducible Chimeric Tumour Suppressors (LI-CTS) that are regulated by anti-oestrogens such as tamoxifen. Tamoxifen lacks side eects, as shown during its use as a preventive agent for breast cancer (Ford and Johnson, 1997) and has been given to more than 7 million people (Gradishar and Jordan, 1997). We used cell lines from head and neck cancers, since it is the sixth most common cancer worldwide (Shah and Lydiatt, 1995) , and accounts for over 40% of cancers in developing countries such as India (Sankaranar-A. , ER T1 -CTS and ER T2 -CTS expression plasmids and transactivation was measured by luciferase assays using a minimal p53 responsive reporter (p53 CON), 24 h after the end of the transfection. CMV lacZ was used as an internal control to measure the transfection eciency. Fold activation is the ratio of the activities of the test and control (transfection of only the reporter) either in absence (denoted by 0) or presence of the ligands. Three synthetic oestrogen antagonists such as tamoxifen (Tam, T) and a 4-hydroxytamoxifen (OHT), but not 17b-oestradiol (Danielian et al., 1993) . The hER T LBD was fused to either the N-or C-termini of CTS1, to generate ER T -CTS and CTS-ER T ( Figure  1A ). ER T1 -CTS and ER T2 -CTS, with potentially improved properties due to further mutations [G400V/L539A/L540A and G400V/M543A/L540A, respectively (Feil et al., 1997) ], were also made.
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The four constructs were tested by transient transfection in HSC-2, a head and neck carcinoma cell line. Without ligand, none of the constructs aected the basal level of a reporter containing consensus p53 motifs (p53 CON: Figure 1B) . The mixed agonist/antagonist, OHT, induced ER T -CTS and CTS-ER T optimally at 10 77 M. The`pure' antioestrogens, ICI 164384 and ICI 182780 (Wakeling, 1995) induced transactivation, which at the higher concentrations was similar to OHT. The optimum 10 77 M concentration was used for subsequent experiments. ER T1 -CTS and ER T2 -CTS were less ecient than ER T -CTS or CTS-ER T , showing that the additional mutations did not improve the LI-CTS ( Figure 1B) . Control experiments showed that the natural steroid, 17b-oestradiol (E2), did not induce transactivation, and pGUP.PA8 (the parental vector for p53CON) gave basal levels of luciferase activity under all conditions ( Figure 1C ), indicating that activation by LI-CTS was speci®c for arti®cial antagonists of the oestrogen receptor and was mediated by p53 motifs. , Figure  2A) . Interestingly, the bax promoter, from a proapoptotic gene, was activated to the greatest extent (Oltvai et al., 1993) . The level of induction by LI-CTS in dierent head and neck cell lines was then compared. HSC-2 cells are p53 null (Sakai and Tsuchida, 1992) , PAP and HAN express functionally mutant forms of p53 and RPMI 2650 produce wild type p53 (Argentini M, Barboule N, Wasylyk B, Muller D and Abecassis J, manuscript in preparation). The cell lines also dier in the level of expression of HDM2 ( Figure 2B ). LI-CTS transactivated in a ligand dependent manner in all of these cell lines ( Figure 2C ). CTS-ER T was expressed at similar levels in the absence or presence of ligands ( Figure 2D , lanes 1 ± 5). We then studied the induction of endogenous p53 responsive genes by LI-CTS, CTS1 and p53 in HSC-2. There were signi®cant increases in the levels of Bax, p21 WAF1/CIP1 and HDM2 ( Figure 2D ; the internal control TBP showed equal loading). Induction of Bax by CTS-ER T was comparable to CTS1 and more than p53 at the tested time point ( Figure 2D , lanes 6 ± 11).
CTS-ER
T also induced p21 WAF1/CIP1 in PAP ( Figure 2D , lanes 20 ± 23 and data not shown). These results show that LI-CTS induce p53 responsive endogenous genes in head and neck cell lines.
LI-CTS are resistant to degradation by HDM2, are transcriptionally more active than CTS1 and p53, and are transported from the cytoplasm to nucleus upon ligand addition HDM2 inhibits transactivation by p53 (Momand et al., 1992) and stimulates its degradation Kubbutat et al., 1997) . LI-CTS has the heterologous VP16 transactivation domain in the place of the HDM2 binding region, which should make it insensitive to HDM2 mediated inhibition and degradation. As shown above, LI-CTS was active in dierent cell lines that express various levels of HDM2 ( Figure 2B ,C). Over-expression of exogenous HDM2 did not aect the activities of ER T -CTS, CTS-ER T and CTS1, whereas p53 was inhibited ( Figure 3A ). Exogenous HDM2 also did not aect the level of CTS-ER T protein expression, nor its ability to induce an endogenous gene (p21
; Figure 3B ). We then compared the relative activities of p53, CTS1 and CTS-ER T by studying the kinetics of transactivation from 1 ± 72 h post-transfection ( Figure  3C ). The mdm2 reporter was activated within 3 ± 4 h by CTS-ER T and CTS1, which was faster than by p53.
E.
F. 
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Ligand inducible tumour regression S Sengupta et al transfection ( Figure 3D ). These results show that the LI-CTS activate to higher levels and for a longer period than p53 or CTS1. We also studied the kinetics of induction of endogenous p53 responsive genes ( Figure 3E ). Following addition of ligand, p21
and HDM2 (data not shown) were induced by 2 h, whereas Bax was induced to a higher level and reached a maximum level by 24 h, by which time 60 ± 80% of the transfected cells were apoptotic (see below). The kinetics of induction of the endogenous genes are compatible with the results with the reporter. Ligands induce nuclear transport of the oestrogen receptor and proteins fused to its ligand-binding domain. We studied the eect of ligand on the cellular localization of CTS-ER T by immunocyto¯uorescence with a speci®c antibody. Following ligand addition, CTS-ER T started to accumulate in the nucleus by 2 h (data not shown) and was mainly nuclear by 8 h ( Figure 3F ). In control untreated cells the protein remained cytoplasmic. These results indicate that LI-CTS are regulated through intracellular re-localization.
LI-CTS kills tumour cells in a ligand dependent manner
To study induction of apoptosis, HSC-2 cells were transfected with expression vectors for LI-CTS and b gal, ligand was added, and after dierent times the cells were examined morphologically ( Figure 4A ), for PARP cleavage ( Figure 4B ) and for DNA fragmentation ( Figure 4C ). There were ligand and LI-CTS dependent morphological changes within 6 h (data not shown), and by 24 h the number of surviving cells decreased by 40 ± 50%, and 70 ± 80% of b-gal expressing cells had visual signs of apoptosis ( Figure 4A and data not shown).
Cleavage and loss of full length PARP is an early marker of apoptosis. The full length 116 kD protein is initially cleaved to a 89 kD fragment, which is subsequently degraded at dierent rates depending on the cell line (McGowan et al., 1996; Shah et al., 1996) . LI-CTS in the presence of ligand caused a decrease in full length PARP and a marginal increase in cleaved PARP ( Figure 4B ).
DNA degradation into nucleosome size fragments is a hall-mark of apoptosis. Low molecular weight DNA was extracted from transfected cells, end labelled by incubation with [a-32 P]dATP and Taq DNA polymerase, and analysed by gel electrophoresis. Nucleosome ladders were produced by LI-CTS in the presence of ligand ( Figure 4C , lanes 2 ± 5). The comparison of the intensities of the ladders indicates that ligand stimulates DNA degradation (compare lanes 2 ± 5 with 1) and that ICI 182780 is more ecient than OHT, at least in this assay ( Figure 4C ).
The preceding experiments involved short term transfections in which exogenous proteins are usually over-expressed for a short period of time. In order to approach physiological conditions, long term colony formation assays were performed with HSC-2 ( Figure  5 
) and PAP (data not shown). LI-CTS (ER T -CTS and CTS-ER
T ) clearly decreased the number of colonies in a ligand dependent manner, and more eciently with the two ICI compounds than with OHT. LI-CTS with ligand were more ecient than CTS but slightly less eective than p53. Ligands had no eect either alone or with p53 or CTS1.
Stable clones expressing CTS-ER T
In order to study the function of LI-CTS in long term assays and in vivo, stable clones were established with the CTS-ER T construct in HSC-2 cells, that do not express p53 at a detectable level. ER T -CTS clones were not obtained, possibly because of a very low level of leaky activity, that is only detectable with long term culture. Two independent CTS-ER T clones (A-47, A-73) and a control clone established with empty vector (E-1, see control lane, Figure 6A ) were characterized in detail. A-47 and A-73 expressed similar levels of CTS-ER T that co-migrated with in vitro translated protein (IVT; Figure 6A ). Ligand addition stimulated expression of p53 responsive endogenous genes in the CTS-ER T clones ( Figure 6B ), and not in the control clone (data not shown). As in transient transfections, p21 WAF1/CIP1 was induced earlier than HDM2 and Bax. The levels of the three proteins peaked at 72 h and decreased thereafter ( Figure 6B ), probably due to a decrease in the number of cells ( Figure 6C 
D.
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PARP cleavage in the CTS-ER T clones, indicating that the introduced LI-CTS induced apoptosis (data not shown).
We studied clone cell survival in the presence and absence of ligand. CTS-ER T clone cells were plated, incubated for various times and then stained ( Figure  6C ) and counted to measure the percentage of viable cells ( Figure 6D ). In the presence of ligand there was a progressive loss of cells ( Figure 6C ), and decrease in the proportion of viable cells, such that by 120 h there E.
Figure 7 LI-CTS inhibits tumour formation and regresses tumours. (A) A-73 (CTS-ER
T clone) cells (1610 6 ) were injected subcutaneously into 6 week-old-female Crl:nu/nu (CD1) mice. The mice were treated from the same day intra-peritoneally for 5 days with tamoxifen or ICI 182780. After 10 weeks the mice were sacri®ced, dissected and the tumours observed. The tumor volumes 10 weeks after treatment are given. (B) A-73 (®lled symbols) and A-47 (open symbols) clones were used to study the ability of ligands to inhibit tumour formation in nude mice. Tumour volumes (cubic mm) in the mice were measured every week. The frequency of tumour formation in the three groups of experimental mice (n=8 in each experimental group) was monitored. Tumour burden (frequency of tumour formation6tumour volume) was plotted against time of treatment. The values are the averages for all the mice in each experimental group (standard deviations are presented, not seen in some since they are small). Figure 6D ). In the controls, in the absence of ligand, the cells grew ( Figure 6C ), remained viable ( Figure 6D ), and ultimately attained con¯uency.
Anti-tumour activity of LI-CTS in mouse xenografts
To test whether LI-CTS can inhibit tumour formation, A-47 and A-73 CTS-ER T clones were injected subcutaneously into 6 week-old female Crl:nu/nu (CD1) mice. Tamoxifen or ICI 182780 treatment was started on the day of injection and continued for 5 days. After 10 weeks, the mice were sacri®ced, dissected and tumours were observed at the site of injection. There was a considerable dierence in the size of the tumours in control (oil) and ligand treated animals, especially ICI 182780 (see Figure 7A) . No tumours were detected at other sites (data not shown). In some mice, injected with A-73 cells and treated with ICI 182780, there were no tumours even after 20 weeks (data not shown). Ligand treatment clearly decreased the tumour burden (frequency of tumour formation6tumour volume; Figure 7B ). ICI 182780 was always much more effective than tamoxifen, even though a tenfold lesser amount was used.
To study tumour regression, the tumours were allowed to grow to a mean volume of 200 cubic mm before treatment with ligand or vehicle. ICI 182780 or tamoxifen (data not shown) induced CTS-ER T tumour regression, starting from the ®rst week of treatment ( Figure 7C ), but had no eect on control tumours (E-1 clone, data not shown). In the absence of ligand the tumours continued to grow. The ligand eects were apparently long lasting, since the tumour volume did not increase even 10 weeks after the beginning of the treatment.
We studied whether tumour regression resulted from apoptosis, by analysing tumour extracts for Bax expression by Western blotting, and tumour sections by both the TUNEL assay (which detects DNA fragmentation) and morphologically. Ligand treatment reproducibly increased Bax levels in the CTS-ER T tumours compared to non-treated or control tumours ( Figure 7D and data not shown). CTS-ER T continued to be expressed in the tumours ( Figure 7D ). ICI 182780 treated tumours contained many TUNEL positive cells, whereas there was no evident staining in non ligand treated tumours ( Figure 7E,a,c) . The TUNEL staining was heterogeneous, with staining in nuclear sized structures (bold arrrows), and smaller fragmented nuclei (smaller arrows) probably representing dierent stages of apoptosis. Apoptosis was also detected by morphological criteria, following Hematoxyline-Eosine (H-E) staining. Control vehicle treated tumours appeared normal, whereas many of the cells in the ICI 182780 treated tumours contained cytoplasmic vesicles and pycnotic micronuclei ( Figure 7E,b,d ; see arrows).
Discussion
In order to make regulatable and ecient p53 derivatives that could potentially be useful for gene therapy and other uses, we made LI-CTS which are (a) regulatable ex vivo and (b) insensitive to various cellular and viral inhibitors of p53. We made use of CTS1, which has the interesting properties of being selectively active in tumour compared to normal cells and being resistant to inactivation by Mdm2, mutant p53 and E6 (see Introduction and Conseiller et al., 1998) . To regulate CTS1 we generated the LI-CTS that are ligand inducible through mutated ligand binding domains from the human oestrogen receptor (hER T -LBD). CTS-LBD fusion proteins are transcriptionally inactive in the absence of synthetic ligands or in the presence of natural steroids (E2:17b-oestradiol) but are activated by oestrogen antagonists (OHT, ICI 164384 and ICI 1827800). Ligand dependent transactivation was observed in every cell type and with every promoter tested. It is notable that LI-CTS activates the pro-apoptotic gene, bax more eciently than several cell cycle genes (such as cyclin G and p21 WAF1/CIP1 ). This selectivity could result from sequence changes in LI-CTS that alter its speci®city for dierent promoters.
p53 is regulated by intracellular transport. p53 is transported to the cytoplasm by HDM2 for degradation Roth et al., 1998 ). This regulation is not possible for LI-CTS, since it lacks the HDM2 binding domain. In fact, the LI-CTS are active in cell lines with high levels of HDM2, they are resistant to inactivation and degradation by exogenous HDM2. Regulation by the ER T LBD was preferred to those conferred by the thyroid and retinoid receptors LBDs, which, in the absence of ligand, are not inactive but rather actively repress transcription (Baniahmad et al., 1995; Casanova et al., 1994) . The corresponding fusion proteins might actively repress p53 regulated gene, thereby aecting cellular functions in the uninduced state. Furthermore, repression is associated with p53 mediated apoptosis (Sabbatini et al., 1995) . LI-CTS is probably held in the cytoplasm by heat shock proteins, chaperonins and immunophillins, similar to ER (Smith and Toft, 1993) . As expected, p53 promoters were not repressed by LI-CTS in the absence of ligand. LI-CTS begins to move within 2 h of ligand addition and is completely nuclear after 6 h. Once into the nucleus, the protein may dimerize through the ligand binding domain, as well as the arti®cial lucine zipper. Transactivation by LI-CTS is detectable within 3 h, which is compatible with the rate of nuclear entry. The C-terminal region of p53 is involved in nuclear shuttling. Cytoplasmic sequestered wild type p53 can be relocated to the nucleus by a Cterminal peptide (Ostermeyer et al., 1996) . The tetramerization domain contains a nuclear export signal that regulates sub-cellular localization of p53 by masking the NES (Liang et al., 1998; Stommel et al., 1999) . LI-CTS is not aected by these mechanisms since the C-terminal tetramerization domain has been removed (Conseiller et al., 1998) . Hence, LI-CTS is regulated by ligand and nuclear import.
Ligand induction of LI-CTS results in growth suppression and/or apoptosis, as demonstrated by transient expression, clonogenic assays and in stable lines expressing CTS-ER T . The ICI compounds are consistently better inducers, since they are pure agonists, whereas OHT is a mixed agonist/antagonist (Wakeling, 1995) . Interestingly, LI-CTS was more active and for a longer duration than CTS1 or p53, and was more ecient than CTS1 at inhibiting colony formation. Most importantly, and unlike p53 or CTS1, the apoptotic ability of LI-CTS can be regulated ex vivo and hence can be used in vivo as a gene therapy tool. Ligand inhibits tumour formation in nude mice by cell lines expressing CTS-ER T . Furthermore, it regresses established tumours. The pro-apoptotic protein Bax is induced in the tumours, indicating that Bax has a role in tumour regression, in contrast to some reports (Knudson et al., 1995; Yin et al., 1997) . We have also observed that the LI-CTS are capable of eciently inhibiting tumour formation even in the presence of cancer cells which have not been genetically modi®ed by the introduction of the transgene, indicating that the surrounding cells may be killed by the bystander eect (S Sengupta and B Wasylyk, 1999, unpublished results) .
Parallel studies have shown that p53 fused to ER T LBD induces rapid apoptosis through Fas transport from cytoplasmic reticulum (Bennett et al., 1998) . We have no evidence that LI-CTS has similar eects, a dierence that could be due to the conditions used or the constructs. p53 ER TM has been studied in cell lines in vitro in serum deprived cells. It remains to be seen how its activity is aected in vitro by HDM2 and mutant p53 and whether they are ecient in mice in vivo in regressing preformed tumours. We studied LI-CTS by transient expression, since this is functionally analogous to the burst of expression following adenovirus infection (Akli et al., 1993) . Later after infection the titre decreases, but the therapeutic potential remains intact Le Gal La Salle et al., 1993) . This is similar to the stable clones, in that LI-CTS is expressed at low levels, but is capable of inducing apoptosis in a ligand dependent manner. The rates of activation are similar to equivalent fusion proteins with fos (Bakin and Curran, 1999) and MEK1 (Treinies et al., 1999) .
In Phase I human trials a small but signi®cant percentage of patients did not respond to wild-type p53 based treatments Schuler et al., 1998) . Tumour cells have various mechanisms that inactivate wild-type p53, including over-expression of HDM2 (Momand et al., 1998) , HPV 16 or 18 E6 expression (Schener et al., 1991) , and the transdominant eects of mutant p53s (Milner and Medcalf, 1991) . The alternate LI-CTS based strategy is more rational than the delivery of wild-type p53, as it can be regulated ex vivo and at the same time is not inactivated in a tumour environment. Adenovirus mediated regulatable gene expression have been recently attempted in vivo (Burcin et al., 1999) . LI-CTS could be useful in the production of adenovirus vectors because it is inactive and non-toxic in the absence of ligand. However, a more practical treatment for accessible cancers, such as head and neck, could be naked gene transfer technology (Coll et al., 1998) . Ligand activation opens up the possibility of temporal control of expression, and even the capability to turn on and o the tumour suppressor a number of times, perhaps thereby improving ecacy. Apart from its use in gene therapy, LI-CTS will be useful in other studies, such as identifying genes involved in apoptosis, and understanding how p53 regulated processes (e.g. angiogenesis) contribute to tumorigenesis in a temporal fashion. These molecules could be used to dissect the pathways that are used by p53 for various functions. Since the N and C terminal domains have been removed to generate LI-CTS, it will be possible to study how these changes aect p53 regulation by cellular and viral factors.
In summary, we have generated novel gene therapy molecules, LI-CTS, that not only retain the functional properties of p53, but also have the advantage of being both regulatable and resistant to inactivation by various cellular and viral proteins that inhibit p53. We have shown that LI-CTS are highly ecient in causing tumour inhibition and regression in mice, in a ligand dependent manner. Hence, these molecules should be of use in tumours that express mutant p53, HDM2 or E6. In fact, amongst gene therapy approaches based on p53, ours provides the ®rst demonstration of regulated regression of tumours.
Materials and methods

Recombinants ER
T -CTS EcoRI¯anked 1 kb fragments containing hER T -, ER T1 -and ER T2 -LBD were PCR ampli®ed from pCre-ER T (Feil et al., 1996) and inserted into the corresponding site of pcDNA3CTS1 (Conseiller et al., 1998) .
CTS-ER
T pcDNA3CTS1 was digested by XhoI and P¯MI giving a 1 kb fragment (step 1). pcDNA3CTS1 was PCR ampli®ed with a primer before the P¯MI site (within CTS1) and a reverse primer excluding the stop codon but incorporating the XhoI site. The product was digested with P¯MI and XhoI to give a 130 bp fragment that was ligated with the 1 kb fragment (from step 1) producing pcDNA3CTS1 without the stop codon (step 3). The modi®ed CTS1 (from step 3) was digested with XhoI to obtain a 1.1 kb linear fragment (step 4) which was ligated with the 1 kb XhoI/SalI fragment from pCre-ER T (incorporating ER T -LBD, step 5) to generate CTS-ER T (step 6). p53CON, pGUP.PA8: a gift from J Shay (Funk et al., 1992) ; p21 WAF1/CIP1 luc: a gift from B Vogelstein (elDeiry et al., 1993); mdm2 luc: a gift from M Oren (Juven et al., 1993) ; cyclin G luc: a gift from M Oren (Zauberman et al., 1995) ; bax luc: a gift from J Reed (Miyashita and Reed, 1995) ; CTS1; a gift from E Conseiller (Conseiller et al., 1998) ; pC53-SN3: a gift from A Levine (Hinds et al., 1990) . CMV-LacZ: (IGBMC, core facility).
Cells
HSC-2: a gift from N Tsuchida (Momose et al., 1989) ; HAN, PAP: cell culture facility, IGBMC; RPMI2650: ATCC (CCL-30).
Transfection
Tumour cell lines were maintained in DMEM+10% FCS+antibiotics at 378C with 5% CO 2 . They were transfected with calcium phosphate (Chen and Okayama, 1987) with 4 mg of total plasmid in 36 mm plates (6-well clusters, Costar 3516). After 16 h the cells were washed with the medium with antibiotic, re-fed with full growth medium in the presence or absence of ligands [tamoxifen and 4-hydroxytamoxifen (Sigma), ICI 164384 (a gift from A Wakeling and Zeneca Pharmaceuticals), ICI 182780 (Tocris)].`Post-transfection' is de®ned as time after addition of fresh medium.
Stable transfections, clonogenic assays
Forty-eight hours post-transfection the cells were washed and cultured in 1 mg/ml G418 for 3 weeks, with medium changes every 5 ± 6 days. Three independent transfections were performed for each experimental point and the whole experiment was repeated three times for the clonogenic assays. Clones were subsequently either visualized by Giemsa staining or isolated and expanded.
Transcriptional activity
Cell lysates were analysed for luciferase and b-galactosidase activities as previously described (Lam and Watson, 1993) . Luciferase was quantitated using a Microlumat LB96P luminometer (EG&G Berthold). In situ b-galactosidase stained cells (Bossy-Wetzel et al., 1997) were visualized under a light microscope.
Western blots
Tumour samples were sonicated with an Ultra-Turrax (Janke and Kunkel) in RIPA buer, high speed centrifuged and the supernatant used for analysis. Cell lines were lysed directly in RIPA buer, protein content estimated by Bio-Rad protein assay. Equal quantities were fractionated by SDS ± PAGE transferred onto nitrocellulose membranes (Schleicher and Schuell) and processed for Western blotting. The various antibodies used were: (a) PARP [a gift from G de Murcia (Kaufmann et al., 1993) ], (b) VP16 [2GV4, (White et al., 1992) ], (c) Bax (N20, Santa Cruz Biotechnology), (d) p21 WAF1/ CIP1 (1WA-IC581, IGBMC core facility), (e) TBP [3G3, (Brou et al., 1993) ], (f) HDM2 [2A10 (Chen et al., 1993) ], (g) p53 [DO-1 (Vojtesek et al., 1992) ] and (h) hER T -LBD [F3, (Ali et al., 1993) ]. Appropriate peroxidase coupled anti rabbit or mouse secondary antibodies were used (Jackson Laboratories). The blots were revealed by chemiluminescence (Pierce Super Signal).
Immuno¯uorescence
The cells were ®xed with 4% paraformaldehyde for 30 min at room temperature and the primary antibody (F3) was used at a dilution of 1 : 1000. The cells were visualized under ā uorescence microscope (Wasylyk et al., 1999) .
DNA fragmentation
Low to medium molecular weight DNA was extracted (Roy et al., 1992) , treated with phenol/chloroform and ethanol precipitated. Half of the extracted material was radio-labelled with [a-32 P]dATP and Taq DNA polymerase (Eldadah et al., 1996) , electrophoresed on 1.5% TBE gels, transferred to nylon membrane (Hybond) and visualized by autoradiography.
Viability assays
Cells (1610 5 ) were plated, incubated with or without the ligands and stained with Giemsa. Viable and apoptotic cells were identi®ed by acridine orange/ethidium bromide uptake and visualized under a¯uorescence microscope.
Tumours in mice
LI-CTS clones (1610 6 cells) were injected subcutaneously in 6 week-old female Crl:nu/nu (CD1) mice (Charles River France). Ligand was administered either immediately or after tumour growth. Solutions in 100% ethanol were suspended in autoclaved oil by sonication (®nal concs: 10 mg/ml tamoxifen and 1 mg/ml ICI 182780) and 100 ml injected (i.e. 1 mg tamoxifen and 100 mg ICI 182780 per mouse). Tumour formation, frequency and volume were followed weekly. Tumour burden=number of tumours6tumour volume.
The tumours were ®xed in 4% paraformaldehyde with shaking overnight, dehydrated stepwise in 50, 80 and 100% ethanol, incubated in Histolemon Erba (Carlo Erba), immersed in liquid paran overnight at 568C, embedded in molds and stored at 48C until sectioning.
Histology and TUNEL assay
Tumours were sectioned with a microtome (2040 ReichertJung), mounted onto slides (coated with gelatine for TUNEL), deparanized with LMR-SOL (Labo Moderne) and either stained with Hematoxyline-Eosine or processed for TUNEL (ApopTag plus peroxidase in situ apoptosis detection kit, Intergen).
